Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, ...

Arthrosi Therapeutics doses first patient in replicate pivotal phase 3 REDUCE 1 trial of lead compound AR882: San Diego Wednesday, March 19, 2025, 11:00 Hrs [IST] Arthrosi Therape ...

Type B Meeting Discussion to Accelerate XRx-026 for Gout to NDA ● CALGARY, Alberta, March 19, 2025 (GLOBE NEWSWIRE) -- XORTX ...

Hyperuricemia (HU) is a metabolic disorder characterized by elevated uric acid (UA) levels in the bloodstream, commonly diagnosed when UA levels ...

cdhb.health.nz Objectives To determine the efficacy and safety of allopurinol dose escalation using a treat-to-target serum urate (SU) approach. Methods A randomised, controlled, parallel-group, ...

Type B Meeting Discussion to Accelerate XRx-026 for Gout to NDA CALGARY, Alberta, March 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Fra ...

Discover Protalix BioTherapeutics' Q4 2024 earnings insights, including record revenues, pipeline advancements, and future growth prospects.

Joint Pain Latest News and Updates, Special Reports, Videos & Photos of Joint Pain on India TV. Articles on Joint Pain, Complete Coverage on Joint Pain ...

Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Fiscal Year 2024 Financial and Business Results Conference Call. As a reminder, this conference call is being ...

Gouty arthritis is a common inflammatory arthritis caused by the deposition of monosodium urate (MSU) crystals in joints with the prevalence of 1% to 3% in China. Interleukin 1-β (IL-1β) is a key ...